Cargando…

Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects

Extensive damage to nigrostriatal dopaminergic neurons leads to Parkinson’s disease (PD). To date, the most effective treatment has been administration of levodopa (L-DOPA) to increase dopaminergic tone. This treatment leads to responses that vary widely among patients, from predominantly beneficial...

Descripción completa

Detalles Bibliográficos
Autores principales: Albarrán-Bravo, Sacnité, Ávalos-Fuentes, José Arturo, Cortés, Hernán, Rodriguez-Sánchez, Marina, Leyva-García, Norberto, Rangel-Barajas, Claudia, Erlij, David, Florán, Benjamín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770442/
https://www.ncbi.nlm.nih.gov/pubmed/31480516
http://dx.doi.org/10.3390/biom9090431
_version_ 1783455473850122240
author Albarrán-Bravo, Sacnité
Ávalos-Fuentes, José Arturo
Cortés, Hernán
Rodriguez-Sánchez, Marina
Leyva-García, Norberto
Rangel-Barajas, Claudia
Erlij, David
Florán, Benjamín
author_facet Albarrán-Bravo, Sacnité
Ávalos-Fuentes, José Arturo
Cortés, Hernán
Rodriguez-Sánchez, Marina
Leyva-García, Norberto
Rangel-Barajas, Claudia
Erlij, David
Florán, Benjamín
author_sort Albarrán-Bravo, Sacnité
collection PubMed
description Extensive damage to nigrostriatal dopaminergic neurons leads to Parkinson’s disease (PD). To date, the most effective treatment has been administration of levodopa (L-DOPA) to increase dopaminergic tone. This treatment leads to responses that vary widely among patients, from predominantly beneficial effects to the induction of disabling, abnormal movements (L-DOPA induced dyskinesia (LID)). Similarly, experimental studies have shown animals with widely different degrees of LID severity. In this study, unilateral injections of 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle (MFB) produced more than 90% depletion of dopamine in both the striatum and the substantia nigra reticulata (SNr) of rats. Population analysis showed that dopamine depletion levels were clustered in a single population. In contrast, analysis of abnormal involuntary movements (AIMs) induced by L-DOPA treatment of 6-OHDA-lesioned animals yielded two populations: one with mild LID, and the other with severe LID, which are also related to different therapeutic responses. We examined whether the severity of LID correlated with changes in dopamine 3 receptor (D3R) signaling because of the following: (a) D3R expression and the induction of LID are strongly correlated; and (b) dopaminergic denervation induces a qualitative change in D3R signaling in the SNr. We found that the effects of D3R activation on cAMP accumulation and depolarization-induced [(3)H]-gamma-aminobutyric acid ([(3)H]-GABA) release were switched. L-DOPA treatment normalized the denervation-induced changes in animals with mild LID. The D3R activation caused depression of both dopamine 1 receptor (D1R)-induced increases in cAMP production and depolarization-induced [(3)H]-GABA release, which were reversed to their pre-denervation state. In animals with severe LID, none of the denervation-induced changes were reversed. The finding that in the absence of identifiable differences in 6-OHDA and L-DOPA treatment, two populations of animals with different D3R signaling and LIDs severity implies that mechanisms intrinsic to the treated subject determine the segregation.
format Online
Article
Text
id pubmed-6770442
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67704422019-10-30 Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects Albarrán-Bravo, Sacnité Ávalos-Fuentes, José Arturo Cortés, Hernán Rodriguez-Sánchez, Marina Leyva-García, Norberto Rangel-Barajas, Claudia Erlij, David Florán, Benjamín Biomolecules Article Extensive damage to nigrostriatal dopaminergic neurons leads to Parkinson’s disease (PD). To date, the most effective treatment has been administration of levodopa (L-DOPA) to increase dopaminergic tone. This treatment leads to responses that vary widely among patients, from predominantly beneficial effects to the induction of disabling, abnormal movements (L-DOPA induced dyskinesia (LID)). Similarly, experimental studies have shown animals with widely different degrees of LID severity. In this study, unilateral injections of 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle (MFB) produced more than 90% depletion of dopamine in both the striatum and the substantia nigra reticulata (SNr) of rats. Population analysis showed that dopamine depletion levels were clustered in a single population. In contrast, analysis of abnormal involuntary movements (AIMs) induced by L-DOPA treatment of 6-OHDA-lesioned animals yielded two populations: one with mild LID, and the other with severe LID, which are also related to different therapeutic responses. We examined whether the severity of LID correlated with changes in dopamine 3 receptor (D3R) signaling because of the following: (a) D3R expression and the induction of LID are strongly correlated; and (b) dopaminergic denervation induces a qualitative change in D3R signaling in the SNr. We found that the effects of D3R activation on cAMP accumulation and depolarization-induced [(3)H]-gamma-aminobutyric acid ([(3)H]-GABA) release were switched. L-DOPA treatment normalized the denervation-induced changes in animals with mild LID. The D3R activation caused depression of both dopamine 1 receptor (D1R)-induced increases in cAMP production and depolarization-induced [(3)H]-GABA release, which were reversed to their pre-denervation state. In animals with severe LID, none of the denervation-induced changes were reversed. The finding that in the absence of identifiable differences in 6-OHDA and L-DOPA treatment, two populations of animals with different D3R signaling and LIDs severity implies that mechanisms intrinsic to the treated subject determine the segregation. MDPI 2019-09-01 /pmc/articles/PMC6770442/ /pubmed/31480516 http://dx.doi.org/10.3390/biom9090431 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Albarrán-Bravo, Sacnité
Ávalos-Fuentes, José Arturo
Cortés, Hernán
Rodriguez-Sánchez, Marina
Leyva-García, Norberto
Rangel-Barajas, Claudia
Erlij, David
Florán, Benjamín
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
title Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
title_full Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
title_fullStr Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
title_full_unstemmed Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
title_short Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
title_sort severity of dyskinesia and d3r signaling changes induced by l-dopa treatment of hemiparkinsonian rats are features inherent to the treated subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770442/
https://www.ncbi.nlm.nih.gov/pubmed/31480516
http://dx.doi.org/10.3390/biom9090431
work_keys_str_mv AT albarranbravosacnite severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT avalosfuentesjosearturo severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT corteshernan severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT rodriguezsanchezmarina severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT leyvagarcianorberto severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT rangelbarajasclaudia severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT erlijdavid severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects
AT floranbenjamin severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects